Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

被引：9

作者：

Passiglia, Francesco ^{[1
,2
]}

Leone, Gianmarco ^{[1
,2
]}

Olmetto, Emanuela ^{[1
,2
]}

Delcuratolo, Marco Donatello ^{[1
,2
]}

Tabbo, Fabrizio ^{[1
,2
]}

Reale, Maria Lucia ^{[1
,2
]}

Bertaglia, Valentina ^{[1
,2
]}

Consito, Lorena ^{[1
,2
]}

Bironzo, Paolo ^{[1
,2
]}

Capelletto, Enrica ^{[1
,2
]}

Novello, Silvia ^{[1
,2
]}

机构：

[1] Univ Turin, S Luigi Gonzaga Hosp, Dept Oncol, Reg Gonzole 10, I-10034 Orbassano, TO, Italy

[2] Univ Turin, AOU San Luigi Gonzaga, Dept Oncol, Orbassano, TO, Italy

来源：

LUNG CANCER | 2021年 / 157卷

关键词：

Immune-checkpoint inhibitors; PD-1; PD-L1; Consolidation; Stage III; Non-small cell lung cancer; PHASE-II; PEMBROLIZUMAB PEMBRO; LUNG; DURVALUMAB; CHEMORADIOTHERAPY; RADIOTHERAPY; IMMUNOTHERAPY; ATEZOLIZUMAB; CHEMOTHERAPY; THERAPY;

D O I：

10.1016/j.lungcan.2021.05.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The PACIFIC trial marked a new era in the treatment of stage III unresectable NSCLC, establishing durvalumab consolidation as new standard of care worldwide, with about 14 % increase of long-term survival and half of the patients alive at 4 years. A series of intensified immune-checkpoint inhibition regimens are currently under investigation in clinical trials in order to optimize the therapeutic benefit obtained in this population, while the identification of personalized approaches as well as the development of effective treatments in the postdurvalumab progression setting represent an actual and controversial topic for clinical lung cancer research. This review describes the current real-word treatment scenario for stage III unresectable NSCLC in Italy, and provides an updated overview of the upcoming therapeutic strategies under clinical investigation, discussing the most relevant challenges and opportunities featuring the post-PACIFIC era.

引用

页码：85 / 91

页数：7

共 40 条

[1] Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution [J].

Abbosh, Christopher ;

Birkbak, Nicolai J. ;

Wilson, Gareth A. ;

Jamal-Hanjani, Mariam ;

Constantin, Tudor ;

Salari, Raheleh ;

Le Quesne, John ;

Moore, David A. ;

Veeriah, Selvaraju ;

Rosenthal, Rachel ;

Marafioti, Teresa ;

Kirkizlar, Eser ;

Watkins, Thomas B. K. ;

McGranahan, Nicholas ;

Ward, Sophia ;

Martinson, Luke ;

Riley, Joan ;

Fraioli, Francesco ;

Al Bakir, Maise ;

Gronroos, Eva ;

Zambrana, Francisco ;

Endozo, Raymondo ;

Bi, Wenya Linda ;

Fennessy, Fiona M. ;

Sponer, Nicole ;

Johnson, Diana ;

Laycock, Joanne ;

Shafi, Seema ;

Czyzewska-Khan, Justyna ;

Rowan, Andrew ;

Chambers, Tim ;

Matthews, Nik ;

Turajlic, Samra ;

Hiley, Crispin ;

Lee, Siow Ming ;

Forster, Martin D. ;

Ahmad, Tanya ;

Falzon, Mary ;

Borg, Elaine ;

Lawrence, David ;

Hayward, Martin ;

Kolvekar, Shyam ;

Panagiotopoulos, Nikolaos ;

Janes, Sam M. ;

Thakrar, Ricky ;

Ahmed, Asia ;

Blackhall, Fiona ;

Summers, Yvonne ;

Hafez, Dina ;

Naik, Ashwini .

NATURE, 2017, 545 (7655) :446-+

[2] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold [J].

Arulananda, Surein ;

Mitchell, Paul .

TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 :S388-S392

[5]

Bi N., 2020, INT ASS STUDY LUNG C

[6] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer [J].

Bradley, Jeffrey D. ;

Hu, Chen ;

Komaki, Ritsuko R. ;

Masters, Gregory A. ;

Blumenschein, George R. ;

Schild, Steven E. ;

Bogart, Jeffrey A. ;

Forster, Kenneth M. ;

Magliocco, Anthony M. ;

Kavadi, Vivek S. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Clifford G. ;

Wynn, Raymond B. ;

Koprowski, Christopher D. ;

Olson, Michael R. ;

Meng, Joanne ;

Paulus, Rebecca ;

Curran, Walter J., Jr. ;

Choy, Hak .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) :706-+

[7]

Bradley JD, 2019, J CLIN ONCOL, V37

[8] Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy [J].

Cortellini, Alessio ;

Di Maio, Massimo ;

Nigro, Olga ;

Leonetti, Alessandro ;

Cortinovis, Diego L. ;

Aerts, Joachim G. J., V ;

Guaitoli, Giorgia ;

Barbieri, Fausto ;

Giusti, Raffaele ;

Ferrara, Miriam G. ;

Bria, Emilio ;

D'Argento, Ettore ;

Grossi, Francesco ;

Rijavec, Erika ;

Guida, Annalisa ;

Berardi, Rossana ;

Torniai, Mariangela ;

Sforza, Vincenzo ;

Genova, Carlo ;

Mazzoni, Francesca ;

Garassino, Marina Chiara ;

De Toma, Alessandro ;

Signorelli, Diego ;

Gelibter, Alain ;

Siringo, Marco ;

Marchetti, Paolo ;

Macerelli, Marianna ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Della Gravara, Luigi ;

Inno, Alessandro ;

Michele, De Tursi ;

Grassadonia, Antonino ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Filetti, Marco ;

Santini, Daniele ;

Citarella, Fabrizio ;

Russano, Marco ;

Cantini, Luca ;

Tuzi, Alessandro ;

Bordi, Paola ;

Minuti, Gabriele ;

Landi, Lorenza ;

Ricciardi, Serena ;

Migliorino, Maria R. ;

Passiglia, Francesco ;

Bironzo, Paolo .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)

[9] Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study [J].

De Ruysscher, Dirk ;

van Baardwijk, Angela ;

Wanders, Rinus ;

Hendriks, Lizza E. ;

Reymen, Bait ;

van Empt, Wouter ;

Ollers, Michel C. ;

Bootsma, Gerben ;

Pitz, Cordula ;

van Eijsden, Linda ;

Dingemans, Anne-Marie C. .

RADIOTHERAPY AND ONCOLOGY, 2019, 135 :141-146

[10]

Durm G.A, CANCER, V126

← 1 2 3 4 →